https://www.selleckchem.com/pr....oducts/R7935788-Fost
1%). Tepotinib was generally well tolerated and the RP2D (500 mg) showed promising efficacy and, therefore, a positive benefit-risk balance in sorafenib pretreated aHCC with MET overexpression. ClinicalTrials.gov NCT02115373. ClinicalTrials.gov NCT02115373.Radiotherapy is essential to the treatment of nasopharyngeal carcinoma (NPC) and acquired or innate resistance to this therapeutic modality is a major clinical problem. However, the underlying molecular mechanisms in the radiation resistance in NPC are not fully understo
Tycka om
Kommentar
Dela med sig
